JP MORGAN/CALL/BOSTON SCIENTIFIC/82/0.1/15.11.24 | Market Closed - Börse Stuttgart 02:36:13 31/05/2024 pm IST | ||
| 0.49 EUR | -3.92% |
|
| 1 month | +11.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 0.49 | -3.92% |
| 30/24/30 | 0.51 | +4.08% |
| 29/24/29 | 0.49 | -12.50% |
| 28/24/28 | 0.56 | -.--% |
| 27/24/27 | 0.56 | +16.67% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 02:36 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JK8C45 |
| ISIN | DE000JK8C452 |
| Date issued | 25/04/2024 |
| Strike | 82 $ |
| Maturity | 15/11/2024 (166 Days) |
| Parity | 10 : 1 |
| Emission price | 0.14 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.56 € |
|---|---|
| Lowest since issue | 0.38 € |
| Spread | 0.04 € |
| Spread % | 7.27% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
75.57
USD
Average target price
82.06
USD
Spread / Average Target
+8.59%
- Stock Market
- Warrants
- Warrant
